News
06-01-2015, 03:54 AM
Promising clinical trial results presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
More... (http://www.news-medical.net/news/20150601/Investigational-anti-cancer-agent-ONT-380-shows-activity-against-HER22b-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20150601/Investigational-anti-cancer-agent-ONT-380-shows-activity-against-HER22b-breast-cancer.aspx)